share_log
Breakings ·  Sep 16 20:00
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment